POZEN Inc., headquartered in Chapel Hill, NC, is a progressive pharmaceutical company committed to transforming medicine that transforms lives. POZEN’s unique in-source business model has been proven through our success in gaining U.S. FDA approval of two self-invented products in two years – something almost no other small pharmaceutical company has achieved. Moving forward, POZEN continues to be dedicated to addressing unmet needs and developing affordable medicines for patients and physicians.
Since our founding in 1996, POZEN has had a long, successful history of creating novel pharmacologic agents by combining existing drug therapies that result in superior patient outcomes. This approach allows for a potentially higher success rate than NCE (new chemical entity) development.
POZEN pioneered the concept of a strategic in-source drug development company whose products would be marketed by strong commercial partners. This model has allowed POZEN to commit nearly all our resources to developing new products while avoiding the high costs associated with basic research, manufacturing, and marketing. By virtue of the initial upfront payments, milestone payments, and ongoing royalties from partnerships, POZEN has been exclusively self-funding since the Initial Public Offering (IPO) in 2000.
PA Product Portfolio
POZEN’s active PA product portfolio is focused on designing cost-effective, integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The PA product portfolio has the potential to benefit the millions of Americans who use daily aspirin to treat cardiovascular disease, osteoarthritis and potentially other diseases.
The first candidates within the PA product portfolio are PA8140 and PA32540. They are coordinated-delivery tablets combining immediate-release omeprazole (40 mg), a proton pump inhibitor (PPI), layered around pH-sensitive enteric-coated aspirin (81 mg or 325 mg) core. The pivotal Phase III trials of PA32540 are complete. Top-line results were announced in March 2012 and presented at both ACG and AHA in October and November 2012, respectively; the New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in March 2013. See the Posters & Publications page for more information.
To maximize the global sales potential of the PA product portfolio, identifying the right partner for PA8140 and PA32540, who can bring this potentially life-saving product to patients, has been a key activity for POZEN. In September 2013, we signed an exclusive license agreement with Sanofi US for the commercialization of PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. Ex-US partnership discussions continue to progress.
Through a partnership with POZEN, the strategic licensing partners would be granted rights to the intellectual property behind PA8140 and PA32540 in the licensed territory and would benefit from POZEN’s manufacturing expertise and supply. Additionally, POZEN completed the initial commercial strategy development for PA8140 and PA32540, including all foundational market research, branding, positioning and innovative commercial marketing plan creation.
For additional information about the PA product portfolio, visit the Development Products – PA Pipeline page.
In April 2008, the Food and Drug Administration (FDA) approved Treximet®(sumatriptan and naproxen sodium) is FDA-approved for the acute treatment of migraine attacks, with or without aura, in adults. In June 2003, POZEN licensed US only rights of Treximet® to GlaxoSmithKline. GlaxoSmithKline (GSK) is responsible for all commercialization activities for Treximet® in the United States. In November 2011, POZEN sold most of the future royalty and milestone payments covering Treximet® sales in the United States to a financial investor for $75 million. However, POZEN retained ex-U.S. rights to develop and market lower dose sumatriptan and naproxen combinations, referred to as MT 400.
MT 400 is POZEN’s proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine headaches. MT 400 has proven to be superior to triptan monotherapy on multiple efficacy endpoints.
In March 2011, POZEN announced a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.
POZEN is actively seeking other licensing partners for the additional available territories.
For additional information about MT 400, visit the Licensed Products – MT 400 page.
VIMOVO™ (naproxen / esomeprazole magnesium) delayed-release tablets, co-developed by POZEN and AstraZeneca, is a fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID), and immediate release esomeprazole, a proton pump inhibitor (PPI). VIMOVO is FDA-approved for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. In August 2006, POZEN licensed worldwide rights for VIMOVO, except for Japan, to AstraZeneca. AstraZeneca is responsible for the commercialization of VIMOVO.